MicroRNA-1908-5p Inhibits Proliferation and Promotes Apoptosis by Targeting PP5 in NSCLC

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jan 15

PMID 31934036

Citations 2

Authors

Yu Li

Luoman Gan

Wentao Li

Shujuan Qin

Guangnan Liu

Affiliations

Soon will be listed here.

Abstract

MicroRNA-1908 is involved in the occurrence and development of various tumors. However, the mechanism of microRNA-1908-5p in the pathogenesis of non-small cell lung cancer (NSCLC) is not thoroughly studied. Protein phosphatase 5 catalytic subunit (PP5), a member of the protein phosphatase catalytic subunit family, may be a target of the microRNA-1908-5p. In order to further explore the mechanism of microRNA-1908-5p, real-time PCR was used to detect the expression of microRNA-1908-5p in non-small cell lung cancer tissues, and analyze the relationship between the expression of microRNA-1908-5p and clinical characteristics of lung cancer patients. The target of microRNA-1908-5p was predicted by bioinformatics and verified by Dual-luciferase assay. The effects of microRNA-1908-5p on the proliferation and apoptosis of lung cancer cells were examined at the cellular level. Nude mice tumorigenesis experiment was used to study the effect of microRNA-1908-5p on cancer cells. Western blot was used to detect the expression of related proteins. The results showed that the expression of microRNA-1908-5p in lung cancer tissues was significantly lower than that in adjacent tissues. The expression of microRNA-1908-5p in the non-metastatic lung cancer tissues was significantly higher than that in the metastatic lung cancer tissues, and the expression of microRNA-1908-5p was closely related to the survival rate of patients. Bioinformatics analysis combined with double luciferase assay showed that PP5 was a significant target of microRNA-1908-5p. Our results suggest that microRNA-1908-5p can regulate the pathogenesis of NSCLC by inhibiting PP5.

Citing Articles

miR-1908 Dysregulation in Human Cancers.

Shen J, Wu Y, Ruan W, Zhu F, Duan S Front Oncol. 2022; 12:857743.

PMID: 35463352 PMC: 9021824. DOI: 10.3389/fonc.2022.857743.

miR1908-5p regulates energy homeostasis in hepatocyte models.

Soubeyrand S, Lau P, Beehler K, McShane K, McPherson R Sci Rep. 2021; 11(1):23748.

PMID: 34887471 PMC: 8660805. DOI: 10.1038/s41598-021-03156-4.

References

Eapen M, Hansbro P, Larsson-Callerfelt A, Jolly M, Myers S, Sharma P . Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities. Drugs. 2018; 78(16):1717-1740. DOI: 10.1007/s40265-018-1001-8. View

Zhang Y, Chen B, Wang L, Wang R, Yang X . Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. Medicine (Baltimore). 2019; 98(3):e13788. PMC: 6370019. DOI: 10.1097/MD.0000000000013788. View

Qi Y, Wang X, Kong X, Zhai J, Fang Y, Guan X . Expression signatures and roles of microRNAs in inflammatory breast cancer. Cancer Cell Int. 2019; 19:23. PMC: 6357482. DOI: 10.1186/s12935-018-0709-6. View

Lu J, Zhan Y, Feng J, Luo J, Fan S . MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 2018; 14(4):390-397. PMC: 5930471. DOI: 10.7150/ijbs.22243. View

Armstrong V, Schoen N, Madhavan K, Vanni S . A systematic review of interventions and outcomes in lung cancer metastases to the spine. J Clin Neurosci. 2019; 62:66-71. DOI: 10.1016/j.jocn.2019.01.006. View

Prezzano K, Ma S, Hermann G, Rivers C, Gomez-Suescun J, Singh A . Stereotactic body radiation therapy for non-small cell lung cancer: A review. World J Clin Oncol. 2019; 10(1):14-27. PMC: 6318482. DOI: 10.5306/wjco.v10.i1.14. View

Teng C, Zheng H . Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer. Oncol Lett. 2017; 14(4):4277-4281. PMC: 5604148. DOI: 10.3892/ol.2017.6714. View

Pratap P, Raza S, Abbas S, Mahdi F . MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res Ther. 2018; 14(2):249-254. DOI: 10.4103/0973-1482.187283. View

Pekarsky Y, Croce C . Noncoding RNA genes in cancer pathogenesis. Adv Biol Regul. 2019; 71:219-223. PMC: 6800108. DOI: 10.1016/j.jbior.2018.12.002. View

10.

Lian D, Wang Z, Liu N . MicroRNA-1908 is a biomarker for poor prognosis in human osteosarcoma. Eur Rev Med Pharmacol Sci. 2016; 20(7):1258-62. View

11.

Magalhaes M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos A, Veiga F . RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018; 15(10):965-982. DOI: 10.1080/17425247.2018.1517744. View

12.

Gurbuz N, Ozpolat B . MicroRNA-based Targeted Therapeutics in Pancreatic Cancer. Anticancer Res. 2019; 39(2):529-532. DOI: 10.21873/anticanres.13144. View

13.

Halford P, Clive A . Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?. Transl Lung Cancer Res. 2018; 7(5):584-592. PMC: 6204410. DOI: 10.21037/tlcr.2018.07.06. View

14.

Lubert E, Hong Y, Sarge K . Interaction between protein phosphatase 5 and the A subunit of protein phosphatase 2A: evidence for a heterotrimeric form of protein phosphatase 5. J Biol Chem. 2001; 276(42):38582-7. DOI: 10.1074/jbc.M106906200. View

15.

Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y . Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer. 2010; 46(9):1692-702. DOI: 10.1016/j.ejca.2010.02.043. View

16.

Guo T, Li J, Zhang L, Hou W, Wang R, Zhang J . Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer. J Cancer Res Clin Oncol. 2018; 145(1):31-48. DOI: 10.1007/s00432-018-2767-5. View

17.

Yu Y, Zuo J, Tan Q, Thin K, Li P, Zhu M . Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark. 2017; 18(3):319-327. DOI: 10.3233/CBM-160254. View

18.

Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak A, Sukari A . Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl). 2018; 9:85-90. PMC: 6207227. DOI: 10.2147/LCTT.S173724. View

19.

Mason J, Blyth B, MacManus M, Martin O . Treatment for non-small-cell lung cancer and circulating tumor cells. Lung Cancer Manag. 2019; 6(4):129-139. PMC: 6310303. DOI: 10.2217/lmt-2017-0019. View

20.

Gupta S, Jadaun A, Kumar H, Raj U, Varadwaj P, Rao A . Exploration of new drug-like inhibitors for serine/threonine protein phosphatase 5 of Plasmodium falciparum: a docking and simulation study. J Biomol Struct Dyn. 2015; 33(11):2421-41. DOI: 10.1080/07391102.2015.1051114. View